Compare Prudential Financial Inc (PRU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Recursion Pharmaceuticals Inc — how do they compare? Prudential Financial Inc trades at $112 (market cap $39.17B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Prudential Financial Inc is far larger — about 18.3× Recursion Pharmaceuticals Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PRU | RXRX | |
|---|---|---|
Market Cap | $39.17B | $2.14B |
Volume | 1,436,917 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $125.13 | $6.79 |
52-Week Low | $92.00 | $2.84 |
Typical Hold Time | 145 Days | 22 Days |
Enterprise Value | $67.95B | $1.66B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $112.36, down 1.04% with bearish technical signals despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent strategic moves include exiting emerging markets with Alexforbes sale and rebranding to Prudential Wealth Advisors, reflecting focus on core operations.
While valuation appears compelling and higher interest rates benefit investment income, analyst sentiment remains cautious with 67.57% hold ratings. The stock faces execution risks from strategic restructuring and competitive pressures in insurance markets. Current price near consensus target of $105.67 suggests limited near-term upside despite fundamental strength.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
